PRELIMINARY REPORT ON IMIPRAMINE (TOFRÃNIL)
Abstract
trials. It is a highly potent drug to be handled with extreme caution and care. Each patient must be seen daily for dosage adjustment and be under constant medical and nursing observations.1. Delay, J., Deniker, P., Ropert, R., Barande, R., and Eurieult, M. : Ann. M#{233}d.-Psyoh., 116: 601, Oct. 1958.2. Perrin,Broussolle, Oct. 1958.J., Lambert, P. A., Balvet, P., and P.: Ann. M#{233}d.-Psych., 116: 602, A. A., andthe highreports( 1-2) potency of thisphenothiazine.Nerv.3. Kurland, & Ment.Dis.,127:Vasconcellos, J.: 378, Oct. 1958.M.D.1(TOFRANIL)E. FELDMAN,Current reports indicate a modest degree of success in the treatment of depressive states with the new energizing compounds (1-5). The clinical similarity of schizophrenic retardation to depressive retardation leads to the speculation that these same compounds might be of some value in theTwenty-three minated prior various reasons: make progress,patients (27%) to the anticipated12 patients-for excessive hyperactivity;were terdate for failure to6 patients-weakness; and weight loss;of schizophrenia(which usually respond adversely to tranquilizer therapy). Eighty-four schizophrenic patients whose clinical states could be characterized as regressed, withdrawn, indifferent, apathetic3 patients-anorexia 1 patient-increased frequency of seizures; 1 patient-furunculosis. The incidence of untoward side effects was 12% and all side effects cleared promptly when medication was discontinued.Many ported of the side effects in other